Paradigm-hf | search
Click here to view Paradigm-hf news from 60+ newspapers.
Bookmark or Share- Angiotensin–Neprilysin Inhibition in Heart Failure with ...The Prospective Comparison of ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin-receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF)...
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart ...LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.)
- Prospective Comparison of ARNI With ACEI to Determine Impact ...The PARADIGM-HF trial showed that sacubitril/valsartan was superior to enalapril in patients with heart failure due to reduced EF. Description:
- Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial ...PARADIGM-HF was designed to compare sacubitril/valsartan to an ACE inhibitor in a broad spectrum of patients with heart failure with reduced EF using the target dose of enalapril shown to reduce mortality, when compared with placebo, in the SOLVD-T treatment trial (Studies of Left Ventricular Dysfunction). 6 When SOLVD-T was conducted ...
- PARADIGM-HF - Wiki Journal ClubBottom Line. Among patients with HFrEF, treatment with an angiotensin receptor-neprilysin inhibitor reduces CV mortality or HF hospitalizations when compared to enalapril. It is also associated with a reduction in all-cause mortality.
More
